CAP

Talkiatry Expands Child & Adolescent Psychiatry to 31 States

Retrieved on: 
Tuesday, August 29, 2023
Insurance, Communication, Rivendell Child, Adolescent and Family Unit, Depression, Violence, Child and adolescent psychiatry, Suicide, CAP, Anxiety, Hope, Woman, Adolescence, Parent, Sadness, Bentham Science Publishers, School, Guardians of the Galaxy, Suicidal ideation, Patient, Grammatical mood, Physician, Psychiatry, Mental health, Social media, Social, Nursing, Birth control, Child

Nation's high-quality psychiatry leader builds on existing 43-state adult psychiatry footprint, now reaching 58 million under-18 patients from coast to coast

Key Points: 
  • Nation's high-quality psychiatry leader builds on existing 43-state adult psychiatry footprint, now reaching 58 million under-18 patients from coast to coast
    Parents raising children in the social media, gun violence and income inequality era deserve timely, affordable child psychiatry access, on their terms
    Led by double board-certified, award-winning psychiatrist Dr. Illese Perlumutter, Talkiatry child & adolescent practice intends to expand nationally, address chronic rural care gaps
    NEW YORK, Aug. 29, 2023 /PRNewswire/ -- National high-quality, in-network psychiatric care leader Talkiatry today announced that it has expanded its child & adolescent psychiatry (CAP) services to 31 states, now reaching 58 million under-18 patients across the country.
  • As the first generations to grow up with social media, issues like body dissatisfaction, social comparison, low self-esteem and disordered eating behaviors are skyrocketing," said Dr. Illisse Perlmutter, Director of Child and Adolescent Psychiatry, Talkiatry.
  • Talkiatry is committed to a continued expansion of its child and adolescent practice, and to reaching kids and families in underserved regions and communities."
  • Within Talkiatry's footprint of over 300 full-time, licensed psychiatrists, it ensures that only board-certified Child & Adolescent psychiatrists see under-18 patients.

L’Officiel Hong Kong successfully registered with the HK SAR Government’s Office for Film, Newspaper and Article Administration

Retrieved on: 
Friday, August 25, 2023
Digital Marketing, Publishing, Film & Motion Pictures, Media, Content Marketing, Communications, General Entertainment, Entertainment, Media Asia Entertainment Group, CAP, Law, Multimedia, Government, SAS, AMTD, Acquisition, Ordinance, Property management

AMTD World Media and Entertainment Group ("AMTD WME"), alongside with L’Officiel Inc. SAS jointly announced that the Government of The Hong Kong Special Administrative Region (“HK SAR”)’s Office For Film, Newspaper and Article Administration has issued a formal letter to AMTD Group (“AMTD”) to inform about the successful registration of the magazine “L’OFFICIEL HONG KONG SAR” in accordance with the Registration of Local Newspapers Ordinance (Laws of Hong Kong, CAP.

Key Points: 
  • AMTD World Media and Entertainment Group ("AMTD WME"), alongside with L’Officiel Inc. SAS jointly announced that the Government of The Hong Kong Special Administrative Region (“HK SAR”)’s Office For Film, Newspaper and Article Administration has issued a formal letter to AMTD Group (“AMTD”) to inform about the successful registration of the magazine “L’OFFICIEL HONG KONG SAR” in accordance with the Registration of Local Newspapers Ordinance (Laws of Hong Kong, CAP.
  • 268) (the Ordinance).
  • This press release features multimedia.
  • View the full release here: https://www.businesswire.com/news/home/20230825005277/en/
    In slightly more than a year post the global acquisition of L’Officiel Inc. SAS, AMTD has already successfully secured governmental permits or completed acquisitions of existing franchisees under the direct owner’s model in important regions including South East Asia (Singapore, Malaysia, Philippines); and Greater Bay Area (Hong Kong).

CAP's 2023 Laboratory Accreditation Program Checklists Continues High Quality Standards

Retrieved on: 
Thursday, August 24, 2023
Research, Medical Devices, Clinical Trials, Other Health, Biotechnology, Pharmaceutical, Health, Science, Oncology, Other Science, CMS, Accreditation, College, Centers for Medicare & Medicaid Services, Clinical Laboratory, CAP, Marie Cassidy, National Voluntary Laboratory Accreditation Program, Medicare, CLIA, Laboratory, Medical device, MD

The College of American Pathologists (CAP) has released the 2023 edition of the Laboratory Accreditation Program checklists.

Key Points: 
  • The College of American Pathologists (CAP) has released the 2023 edition of the Laboratory Accreditation Program checklists.
  • Infused with best practices, our 21 discipline-specific accreditation checklists provide a clear roadmap for not only achieving accreditation but also for running a high-quality laboratory.
  • Checklists are updated annually to help laboratories stay current with rapidly evolving advances in laboratory medicine, technology, and regulatory compliance.
  • The inspectors use the checklists as a tool to evaluate laboratory compliance with the CLIA regulations and the CAP standards for accreditation.

Bionano Laboratories Receives College of American Pathologists (CAP) Accreditation for its Clinical Laboratory

Retrieved on: 
Wednesday, August 16, 2023
Insurance, Accreditation, College, CAP, Biotechnology, National Voluntary Laboratory Accreditation Program, Doctor of Philosophy, CLIA, Laboratory, FACMG, SAN, Quality control, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, OGM, Food, Pharmaceutical industry

SAN DIEGO, Aug. 16, 2023 (GLOBE NEWSWIRE) -- Bionano Laboratories, a laboratory services business of Bionano Genomics, Inc. (Nasdaq: BNGO), today announced that it has received Laboratory Accreditation from the College of American Pathologists (CAP) for its Clinical Laboratory Improvement Amendments (CLIA)-certified reference lab.

Key Points: 
  • SAN DIEGO, Aug. 16, 2023 (GLOBE NEWSWIRE) -- Bionano Laboratories, a laboratory services business of Bionano Genomics, Inc. (Nasdaq: BNGO), today announced that it has received Laboratory Accreditation from the College of American Pathologists (CAP) for its Clinical Laboratory Improvement Amendments (CLIA)-certified reference lab.
  • CAP accreditation is awarded to laboratories that meet stringent requirements and maintain the highest standards for laboratory operations of quality, accuracy, and consistency, as outlined by CAP.
  • CAP accreditation is often required for a clinical service provider to become part of insurance companies’ preferred provider networks for reimbursement.
  • “I want to congratulate Alka and the team at Bionano Labs for achieving this milestone.

Public Comment Period Opens for HPV Testing in Head and Neck Carcinomas Guideline Update

Retrieved on: 
Monday, August 14, 2023
Research, Medical Devices, Clinical Trials, Other Health, Biotechnology, Pharmaceutical, Health, Science, Oncology, Other Science, SCC, College, Capitol, CAP, Marie Cassidy, Pharynx, Pathology, Head, Prognosis, Neck, Doctor of Philosophy, Otorhinolaryngology, Incidence, Dentist, FNA, MD, Patient, Nursing, Comment, HPV, Neoplasm, Hospital, Massachusetts General Hospital, Dentistry

The College of American Pathologists (CAP) is updating the 2017 evidence-based practice guideline, “Human Papillomavirus (HPV) Testing in Head and Neck Carcinomas,” which is available today in draft form for public comment through September 1, 2023 on cap.org.

Key Points: 
  • The College of American Pathologists (CAP) is updating the 2017 evidence-based practice guideline, “Human Papillomavirus (HPV) Testing in Head and Neck Carcinomas,” which is available today in draft form for public comment through September 1, 2023 on cap.org.
  • The incidence of HPV-associated head and neck cancers continue to rise in the United States, with the greatest increase among middle-aged white men.
  • At least 25% and as much as 60% of head and neck cancers worldwide are now associated with high-risk HPV.
  • Following the open comment period, the guideline authors will consider all feedback to finalize the recommendations.

ArtsAI is Inc's Fastest Growing Ad Technology Company Two Years In A Row

Retrieved on: 
Thursday, August 17, 2023
Database, Inc., Partnership, CAP, Intelligence, Nemesis Fighting: MMA Global Invasion, Tech, INC, Sale, SAN, Radio, Artificial intelligence, Growth, AI, Cryptocurrency

SAN FRANCISCO, Aug. 17, 2023 /PRNewswire-PRWeb/ -- ArtsAI today announced it has moved up 27 places on the INC 5000 list to #29, again earning the position as the top ranked Ad Technology company on the list. The Inc. 5000 list is considered the definitive measure of the most successful independent companies in America.

Key Points: 
  • ArtsAI today announced it has moved up 27 places on the INC 5000 list to #29, again earning the position as the top-ranked Ad Technology company on the list.
  • SAN FRANCISCO, Aug. 17, 2023 /PRNewswire-PRWeb/ -- ArtsAI today announced it has moved up 27 places on the INC 5000 list to #29, again earning the position as the top ranked Ad Technology company on the list.
  • "It's an incredible honor for ArtsAI to repeat as the fastest growing private Ad Tech company in America on the INC 5000 list," said ArtsAI CRO Erik Lundberg.
  • We are thrilled to round out the group as the fastest growing Ad Technology solution."

Amprion Announces Granting of European Patents for Seed Amplification Assay Platform

Retrieved on: 
Tuesday, August 15, 2023
Patent, PrP, Intellectual property, CAP, Neurodegenerative disease, Clinical trial, Sutro Biopharma, SAA, Lead, University, Research, CLIA, Laboratory, SAN, Alpha-synuclein, Diagnosis, PMCA, Fine chemical, Nursing, EU, Amprion

SAN DIEGO, Aug. 15, 2023 /PRNewswire/ -- Amprion, a global leader in neurodegenerative disease diagnostics, continues to fortify its Intellectual Property surrounding the company's proprietary methodology for highly sensitive detection of misfolded proteins and amyloid-like aggregates. Recently, fundamental patents have been issued in the EU and UK which expands Amprion's extensive coverage in key geographies. The issued patents apply broadly to the methodology known alternatively as Seed Amplification Assay (SAA), Protein Misfolding Cyclic Amplification (PMCA) and Real-Time Quaking-Induced Conversion (RT-QuiC).  

Key Points: 
  • Recently, fundamental patents have been issued in the EU and UK which expands Amprion's extensive coverage in key geographies.
  • The issued patents apply broadly to the methodology known alternatively as Seed Amplification Assay (SAA), Protein Misfolding Cyclic Amplification (PMCA) and Real-Time Quaking-Induced Conversion (RT-QuiC).
  • Amprion is the only entity, commercial or otherwise, that has issued patents in each of the major misfolded protein categories.
  • Amprion plans to lead and perform all clinical trial collaborations to ensure the highest degree of quality and consistent performance needed by Biopharma partners.

InventHelp Inventor Develops New Storage Unit for Caps (TLS-344)

Retrieved on: 
Monday, August 14, 2023
Sale, Multimedia, Dust, CAP, Mushroom

My design would preserve caps and also prevent them from being discarded throughout a home."

Key Points: 
  • My design would preserve caps and also prevent them from being discarded throughout a home."
  • The patent-pending invention provides a safe and effective way to store caps.
  • In doing so, it ensures that the caps retain their original shape.
  • The invention features a practical design that is easy to use so it is ideal for households, sport cap collectors and individuals with numerous caps.

AVIA and CAP Strongly Support the Passage of Legislation to Amend the IP Code of The Philippines to Allow for Pirate Sites to be Blocked in The Philippines

Retrieved on: 
Tuesday, May 23, 2023
House, Sulfotransferase, Piracy, Music, French Intellectual Property Code, Senate, Lawsuit, Internet service provider, GMA Network, CAP, Reading globe groups, Corporate communication, Kroma Entertainment, IP, Government, AVIA, Video, United States Navy Special Projects Office, Book, Representative, YouGov, Growth, Philippine government response to the COVID-19 pandemic, Reading (legislature), Legislation, Video game

However, the study also showed growing consumer awareness of the damage caused by piracy, with 90% of consumers believing that piracy has negative consequences for the Philippines.

Key Points: 
  • However, the study also showed growing consumer awareness of the damage caused by piracy, with 90% of consumers believing that piracy has negative consequences for the Philippines.
  • Cheetham also noted that earlier this month, Senator Estrada introduced matching legislation in the Senate (Senate Bill 2150) for Congressman Salceda's Bill.
  • This is a landmark achievement for the creative industry, with the bill a step closer to becoming a law.
  • Revisions to the IP code are essential for bolstering a digital landscape that is secure and equitable," she said.

ChromaCode and Protean BioDiagnostics Establish Strategic Partnership to Introduce a HDPCR-based NSCLC Assay in the U.S.

Retrieved on: 
Thursday, August 10, 2023
DNA, Partnership, CAP, NGS, Cancer, National Comprehensive Cancer Network, Genomics, NSCLC, RNA, Lung cancer, Biomarker, Noninvasive prenatal testing, NCCN, Incidence, Patient, Laboratory, Physician, United States Department of Veterans Affairs, Veterans' affairs, Government, FRCPC, High definition, Gene, Pharmaceutical industry, Medical imaging, Proteus, MD

This partnership's goal is to introduce a non-small cell lung cancer (NSCLC) assay, based on ChromaCode's state-of-the-art High Definition PCR (HDPCR™) multiplexing technology, via an early access program.

Key Points: 
  • This partnership's goal is to introduce a non-small cell lung cancer (NSCLC) assay, based on ChromaCode's state-of-the-art High Definition PCR (HDPCR™) multiplexing technology, via an early access program.
  • HDPCR™ represents an innovative approach to deep multiplexing of biomarkers in a single, rapid, cost-effective assay for multiple sample types.
  • Designed for applications in oncology, minimal residual disease, transplant, and noninvasive prenatal testing, the HDPCR™ technology simplifies workflows and reduces processing times.
  • "This strategic partnership with Protean marks a significant step towards bringing the HDPCR NSCLC assay to Florida, a state accounting for approximately 10% of cancer incidence in the US," said Padma Sundar, Chief Business Officer of ChromaCode.